Protein expression of prognostic genes in primary melanoma and benign nevi

[1]  Wang Xiaoyuan,et al.  Identification of prognostic genes and construction of a novel gene signature in the skin melanoma based on the tumor microenvironment , 2021, Medicine.

[2]  J. Becker,et al.  Expression of Mismatch Repair Proteins in Merkel Cell Carcinoma , 2021, Cancers.

[3]  T. Gambichler,et al.  Caucasians with acral lentiginous melanoma have the same outcome as patients with stage- and limb-matched superficial spreading melanoma , 2021, Journal of Cancer Research and Clinical Oncology.

[4]  T. Gambichler,et al.  Multivariate analysis of prognostic factors in patients with nodular melanoma , 2021, Journal of Cancer Research and Clinical Oncology.

[5]  Nuno A. Fonseca,et al.  Tumour gene expression signature in primary melanoma predicts long-term outcomes: A prospective multicentre study , 2020, bioRxiv.

[6]  A. Hauschild,et al.  Prognostic significance of an 11-gene RNA assay in archival tissue of cutaneous melanoma stage I-III patients. , 2020, European Journal of Cancer.

[7]  C. Slingluff,et al.  Gene expression analysis in formalin fixed paraffin embedded melanomas is associated with density of corresponding immune cells in those tissues , 2020, Scientific Reports.

[8]  M. Boyano,et al.  Serum markers improve current prediction of metastasis development in early‐stage melanoma patients: a machine learning‐based study , 2020, Molecular oncology.

[9]  Dennis H. Murphree,et al.  Identification of stage I/IIA melanoma patients at high risk for disease relapse using a clinicopathologic and gene expression model. , 2020, European journal of cancer.

[10]  J. Shao,et al.  Identification of a Gene-Related Risk Signature in Melanoma Patients Using Bioinformatic Profiling , 2020, Journal of oncology.

[11]  Nhat Anh Cao,et al.  Molecular risk prediction in cutaneous melanoma: a meta-analysis of the 31-gene expression profile prognostic test in 1,479 patients. , 2020, Journal of American Academy of Dermatology.

[12]  Lai Xu,et al.  NGS Evaluation of Colorectal Cancer Reveals Interferon Gamma Dependent Expression of Immune Checkpoint Genes and Identification of Novel IFNγ Induced Genes , 2020, Frontiers in Immunology.

[13]  C. Garbe,et al.  Clinical validation of a prognostic 11-gene expression profiling score in prospectively collected FFPE tissue of patients with AJCC v8 stage II cutaneous melanoma. , 2019, European journal of cancer.

[14]  S. Swetter,et al.  Prognostic gene expression profiling in melanoma: necessary steps to incorporate into clinical practice , 2019, Melanoma management.

[15]  C. Berking,et al.  A Prognostic Gene Signature Expressed in Primary Cutaneous Melanoma: Synergism With Conventional Staging , 2018, JNCI cancer spectrum.

[16]  Jeffrey E Gershenwald,et al.  Melanoma staging: Evidence‐based changes in the American Joint Committee on Cancer eighth edition cancer staging manual , 2017, CA: a cancer journal for clinicians.

[17]  A. Hauschild,et al.  Adjuvant Dabrafenib plus Trametinib in Stage III BRAF‐Mutated Melanoma , 2017, The New England journal of medicine.

[18]  P. Ascierto,et al.  Adjuvant Nivolumab versus Ipilimumab in Resected Stage III or IV Melanoma , 2017, The New England journal of medicine.

[19]  F. Edfors,et al.  Gene‐specific correlation of RNA and protein levels in human cells and tissues , 2016, Molecular systems biology.

[20]  I. M. de la Fuente,et al.  Vitronectin and dermcidin serum levels predict the metastatic progression of AJCC I–II early‐stage melanoma , 2016, International journal of cancer.

[21]  V. Gotlieb,et al.  The rapidly evolving therapies for advanced melanoma--Towards immunotherapy, molecular targeted therapy, and beyond. , 2016, Critical reviews in oncology/hematology.

[22]  I. Osman,et al.  Revisiting determinants of prognosis in cutaneous melanoma , 2015, Cancer.

[23]  V. Anne Smith,et al.  Relationship between differentially expressed mRNA and mRNA-protein correlations in a xenograft model system , 2015 .

[24]  L. Ferris,et al.  Gene expression profiling for molecular staging of cutaneous melanoma in patients undergoing sentinel lymph node biopsy. , 2015, Journal of the American Academy of Dermatology.

[25]  Dirk Schadendorf,et al.  Melanoma in 2013: Melanoma—the run of success continues , 2014, Nature Reviews Clinical Oncology.

[26]  L. Chin,et al.  HOXA1 drives melanoma tumor growth and metastasis and elicits an invasion gene expression signature that prognosticates clinical outcome , 2013, Oncogene.

[27]  C. Berking,et al.  A nine-gene signature predicting clinical outcome in cutaneous melanoma , 2013, Journal of Cancer Research and Clinical Oncology.

[28]  S. Wagner,et al.  An Attempt at a Molecular Prediction of Metastasis in Patients with Primary Cutaneous Melanoma , 2012, PloS one.

[29]  C. Robert,et al.  New drugs in melanoma: it's a whole new world. , 2011, European journal of cancer.

[30]  D. Bishop,et al.  Gene Expression Profiling of Paraffin-Embedded Primary Melanoma Using the DASL Assay Identifies Increased Osteopontin Expression as Predictive of Reduced Relapse-Free Survival , 2009, Clinical Cancer Research.

[31]  Yaguang Xi,et al.  The impact of genomics in understanding human melanoma progression and metastasis. , 2008, Cancer control : journal of the Moffitt Cancer Center.

[32]  M. Nosrati,et al.  Osteopontin as a molecular prognostic marker for melanoma , 2008, Cancer.

[33]  A. Eggermont,et al.  Gene expression profiling of primary cutaneous melanoma and clinical outcome. , 2006, Journal of the National Cancer Institute.

[34]  K. Hoek,et al.  Whole-genome expression profiling of the melanoma progression pathway reveals marked molecular differences between nevi/melanoma in situ and advanced-stage melanomas , 2005, Cancer biology & therapy.